Clinical trials
PD-L1 clinical trials
Below are recruiting pd-l1 clinical trials, each written for real people, not researchers. We’re tracking 106 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT06788990RecruitingPhase 2/Phase 3
Study of ficerafusp alfa with pembrolizumab for advanced head and neck cancer
This study tests a new drug called ficerafusp alfa (BCA101) combined with the immunotherapy pembrolizumab for people with advanced head and neck cancer that has not been treated before. The goal is to see if adding ficerafusp alfa helps shrink tumors better than pembrolizumab alone.
Birmingham, AlabamaAges 18 years+ - NCT06305962RecruitingEarly Phase 1
Radioactive drug for advanced PD-L1 positive solid tumors
This trial tests a radioactive medicine (177Lu-anti-PD-L1 sdAb) that delivers radiation to cancer cells with PD-L1 protein, which is found on some solid tumors. It is for people whose cancer has spread or come back after standard treatments.
Kingswood, New South WalesAges 18 years+ - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT06487624RecruitingPhase 1
Study of HCB301 for advanced solid tumors and Hodgkin lymphoma
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
Greenville, South CarolinaAges 18 years+ - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06769152RecruitingPhase 2
HLX43 for advanced gynecological cancers
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Ji'nan, ShandongAges 18–75 - NCT07106892RecruitingPhase 2
Testing HLX43 for advanced colorectal cancer
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
BeijingAges 3 weeks–2 months
Hear when a new PD-L1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pd-l1?
- Yes. Clin2 currently lists 106 recruiting pd-l1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pd-l1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pd-l1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.